• Like

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Comparative study of cefpodoxime

  • 2,304 views
Uploaded on

 

More in: Business , Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
2,304
On Slideshare
0
From Embeds
0
Number of Embeds
2

Actions

Shares
Downloads
63
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Comparative study of Cefpodoxime and to study the market potential for ’s product portfolio.
  • 2. Position Ranbaxy & Daiichi Sankyo combined Merger rank top 20 global June 2008, with pharmaceutical Daiichi Sankyo companies. In public Incorporated in 1961 and went No. 1 Indian Pharma public in 1973 Company Started by Ranbir Global consolidated Singh and Gurbax sales –US $ 1519 Mn Singh 1937 (2009) International 77% Domestic 23%
  • 3. Rantidine Valacyclovir Diclofenac Simvastatin Ofloxacin Co-amoxyclav Imipenem Ciprofloxacin Ceftriaxone Amoxycillin Cefpodoxime Isotretinoin Atorvastatin Ketorolac Cephalexin Loratadine Ginseng
  • 4.  (Cefpodoxime proxetil) is an orally administered, extended spectrum, semi- syntheticantibiotic of the cephalosporin class.  Microbiology: Cefpodoxime is active against a wide spectrum of Gram-positive and Gram- negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime.  FOR PRODUCT PORTFOLIO ◦ CEPODEM-XP (Cefpodoxime + Clavulanic Acid) ◦ CEROXIM (Cefuroxime) ◦ CEROXIM-XP (Cefuroxime + Clavulanic Acid) ◦ RACIPER (Esomeprazole) ◦ RICONIA (Multivitamin) ◦ ALTRAFLAM (Aceclofenac) ◦ SYNASMA (Doxofylline) ◦ & GEMBAX (Gemifloxacin)
  • 5. 1 To know the market share of the Ranbaxy’s Products in Ranbaxy (Pharma) Section. 2 To know about the current products that are giving a tough competition to Ranbaxy. 3 To know about the new competitors that have entered into the market and are trying to capture some of it’s share.
  • 6. Type of Research: Exploratory research Sample unit: Retailer Sample extent: South Delhi Sampling technique: Convenient sampling Sample size: 100 Retailers Data collection methods: Primary methods: (a)Face to face interactions (b) Questionnaire Secondary methods: Company manuals ,Journals ,Magazines & Internet Analysis technique Microsoft Excel has been used for the statistical analysis. Limitations: Sometime respondents refuse to cooperate and it may possible that they give biased and dishonest answers.
  • 7. SALE OF CEPODEM STRIP/WEEK
  • 8. Ranbaxy Product sales/week 90 80 70 60 50 40 30 20 10 0 CEPODEM CEPODEM-XP CEROXIM CEROXIM-XP RACIPER RICONIA ALTRAFLAM-P SYNASMA GEMBAX OVERALL AIIMS MALVIYA NAGAR CHITTARANJAN PARK JANGPURA---BHOGAL NEW FRIENDS COLONY JAMIA NAGAR(OKHLA) OKHLA (FORTIS HOSPITAL)
  • 9. Frequent Doctors Visit. Availability of products More profit and replacement schemes to the chemists Advertisement in medical journals. Cost factor